Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18785421 | 0.84 | OPRM1 (0.49) | OPRM1OPRK1OPRL1OPRD1NPSR1 | |
| SCHEMBL3224569 | 0.80 | OPRM1 (0.48) | OPRM1OPRK1OPRL1OPRD1NPSR1 | |
| SCHEMBL1742229 | 0.80 | OPRM1 (0.71) | OPRM1OPRK1OPRL1OPRD1NPSR1 | |
| SCHEMBL18785469 | 0.78 | OPRM1 (0.48) | OPRM1OPRK1OPRL1OPRD1NPSR1 | |
| SCHEMBL19585998 | 0.76 | MEN1 (0.50) | MEN1KMT2AALDH1A1 | |
| SCHEMBL13317173 | 0.74 | OPRM1 (0.51) | OPRM1OPRK1OPRL1OPRD1NPSR1 | |
| SCHEMBL69083 | 0.74 | OPRM1 (0.56) | OPRM1OPRK1OPRL1OPRD1NPSR1 | |
| SCHEMBL2142315 | 0.74 | OPRM1 (0.51) | OPRM1OPRK1OPRL1OPRD1NPSR1 | |
| SCHEMBL2142366 | 0.73 | CYP3A4 (0.42) | OPRM1OPRK1OPRL1OPRD1NPSR1 | |
| SCHEMBL1489316 | 0.73 | OPRM1 (0.50) | OPRM1OPRK1OPRL1OPRD1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689398-B2 | OXA-Diazaspiro compounds having activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-23 | — | — | US | disclosed |
| US-10689398-B2 | OXA-Diazaspiro compounds having activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-23 | — | — | US | disclosed |
| US-20190002475-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| US-20190002475-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| WO-2017067664-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689398-B2 | OXA-Diazaspiro compounds having activity against pain | OPRD1, SIGMAR1, OPRK1 | OPRM1 5/4885OPRK1 3/4885OPRL1 4/4885 |
| US-20190002475-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | OPRM1 5/4885OPRK1 3/4885OPRL1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.